白细胞介素17A及其受体拮抗剂治疗银屑病的不良反应  

Adverse reactions to interleukin-17A and its receptor antagonists in the treatment of psoriasis

作　　者：王若珺 李若瑜[1] Wang Ruojun;Li Ruoyu(Department of Dermatology and Venereology,Peking University First Hospital,Research Center for Medical Mycology,Peking University,Beijing Key Laboratory of Molecular Diagnosis on Dermatoses,Beijing 100034,China)

机构地区：[1]北京大学第一医院皮肤性病科,北京大学真菌和真菌病研究中心,皮肤病分子诊断北京市重点实验室,100034

出　　处：《中华皮肤科杂志》2021年第2期170-173,共4页Chinese Journal of Dermatology

摘　　要：白细胞介素17A在银屑病的发生发展中具有关键作用。目前,有多种白细胞介素17A及其受体拮抗剂在多个国家上市并应用于银屑病的治疗,取得了明确疗效。然而,该类生物制剂在临床试验阶段及上市后,仍然有多项不良反应报道,包括上呼吸道感染、念珠菌感染、中性粒细胞减少和炎症性肠病等,严重者甚至可危及生命。本文综述3种白细胞介素17A及其受体拮抗剂司库奇尤单抗、ixekizumab和brodalumab的临床安全性。Interleukin(IL)-17A plays a key role in the occurrence and development of psoriasis.To date,several marketed IL-17A and its receptor antagonists have been applied to the treatment of psoriasis,and definite therapeutic effects have been achieved.However,several adverse reactions,including upper respiratory tract infection,Candida infections,neutropenia,inflammatory bowel disease,which can be life-threatening,have been reported in clinical trials and after marketing of these biologics.This review summarizes clinical safety profiles of 3 types of interleukin-17A and its receptor antagonists,i.e.,secukinumab,ixekizumab and brodalumab.

关 键 词：银屑病 生物制剂 白细胞介素17 受体 白细胞介素17 抗体 单克隆 人 药物毒性 感染 白色念珠菌 

分 类 号：R758.63[医药卫生—皮肤病学与性病学]